Abstract
Blocks of purine nucleotide degradation may lead to an accumulation of the intermediates or their metabolites in human body fluids or cells. The accumulation of such intermediates may be toxic to certain cells and may lead to clinical disorders such as immunodeficiency.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HG: Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067–1069, 1972.
Giblett, ER, Ammann AJ, Wara DW, Diamond LK: Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1: 1010–1013, 1975.
Meuwissen HJ, Pickering RJ, Pollara B, Porter IH: Combined Immunodeficiency and Adenosine Deaminase Deficiency: A Molecular Deject. New York, Academic Press, 1975.
Hirschhorn R: Clinical delineation of adenosine deaminase deficiency in Enzyme Defects and Immune Dysfunction, Ciba Foundation Symposium No. 68. Amsterdam, Elsevier, 1979, pp 35–49.
Hirschhorn R, Papageorgiou PS, Kesarwala HH, Taft LT: Amelioration of neurologic abnormalities after enzyme replacement in adenosine deaminase deficiency. N Engl J Med 303: 377–380, 1980.
Schwartz AL, Polmar SH, Stern RC: Abnormal platelet aggregation in severe combined immunodeficiency disease with adenosine deaminase deficiency. Br J Haematol 39: 189–194, 1978.
Lee CH, Evans SP, Rozenberg MC, Bagnara AS, Ziegler JB, Van der Weyden MB: In vitro platelet abnormality in adenosine deaminase deficiency and severe combined immunodeficiency. Blood 53: 464–471, 1979.
Coleman MS, Donofrio J, Hutton JJ, Hahn L, Daoud A, Lampkin B, Dyminski J: Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine-deaminase deficiency and severe combined immunodeficiency disease. J Bioi Chem 253: 1619–1626, 1978.
Cohen AR, Hirschhorn R, Horowitz SD, Rubinstein A, Pol mar SH, Hong R, Martin DW Jr: Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci USA 75: 472–476, 1978.
Schmalstieg FC, Neison JA, Mills GC, Monahan T, Goldman AS, Goldblum RM: Increased purine nucleotides in adenosine deaminase deficiency lymphocytes. J Pediatr 91: 48–51, 1977.
Hershfield MS, Kredich NM, Ownby DR, Ownby H, Buckley R: In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine in adenosine deaminase-deficient patients. J Clin Invest 63: 807–811, 1979.
Kaminska J, Fox IH: Decreased S-adenosylhomocysteine hydrolase in inborn errors of purine metabolism. J Lab Clin Med 96: 141–147, 1980.
Fox IH: Metabolic bases for disorders of purine nucleotide degradation. Metabolism 30: 616–634, 1981.
Polmar SH: Enzyme replacement and other biochemical approaches to therapy of adenosine deaminase deficiency, in Enzyme Defects and Immune Dysfonction, Ciba Foundation Symposium No. 68. Amsterdam, Elsevier, 1979, pp 213–223.
Hirschhorn R, Roegner V, Rubinstein A: Plasma deoxyadenosine, adenosine and erythrocyte dATP are elevated at birth in an adenosine deaminase-deficient child. J Clin Invest 65: 768–771, 1980.
Chen S, Ochs HD, Scott CR: Adenosine deaminase deficiency disappearance of adenosine deoxynucleotides from a patient’s erythrocytes after successful marrow transplantation. J Clin Invest 62: 1386–1389, 1978.
Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rose FS: Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J Clin Invest 68: 1387–1393, 1981.
Glazer RI: Adenosine deaminase inhibitors: Their role in chemotherapy and immunosuppression. Cancer Chemother Pharmacol 4: 227–235, 1980.
Mitchell BS, Koller CA, Heyn R: Inhibition of adenosine deaminase activity results in cytotoxicity to T-lymphoblasts in vivo. Blood 56: 556–559, 1980.
Siaw MFE, Mitchell BS, Koller CA, Coleman MS, Hutton JJ: A TP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci USA 77: 6157–6160, 1980.
Smyth JF, Paine RM, Jackman AL, Harrap KR, Chassin MM, Adamson RH, Johns DG: The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother Pharmacol 5: 93–101, 1980.
Poplack DG, Sallan SE, Rivera G, Holcenberg J, Murphy SB, Blatt J, Lipton JM, Venner P, Glaubiger DL, Ungerleider R, Johns D: Phase 1 study of 2′-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res 41: 3343–3346, 1981.
Grever MR, Siaw MFE, Jacob WF, Neidhart JA, Miser JS, Coleman MS, Hutton JJ, Balcerzak SP: The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57: 406–417, 1981.
Major PP, Agarwal RP, Kufe DW: Clinical pharmacology of deoxycoformycin. Blood 58: 91–96, 1981.
Russell NH, Prentice HG, Lee N, Piga A, Ganeshaguru K, SmythJF, Hoffbrand AV: Studies on the biochemical sequelae of therapy in Thy-acute lymphoblastic leukemia with adenosine deaminase inhibitor 2′-deoxycoformycin. Br J Haematol 49: 1–9, 1981.
Ammann AJ: Immunological aberrations in purine nucleotide phosphorylase deficiencies, in Enzyme Defects and Immune Dysfonction, Ciba Foundation Symposium No. 68. New York, Exerpta Medicus, 1979, pp 55–69.
Cohen A, Guda LJ, Ammann AJ, Staal GEJ, Martin DW Jr: Deoxyguanosine triphosphate as a possible toxic metabolite associated with purine nucleoside phosphorylase deficiency. J Clin Invest 61: 1405–1409, 1978.
Wortmann RL, Andres CM, Kaminska J, Mejias E, Gelfand E, Arnold W, Rich W, Fox IH: Purine nucleoside phosphorylase deficiency: Biochemical properties and heterogeneity in two families. Arthritis Rheum 22: 524–531, 1979.
Hershfield MS: Proposed explanation for S-adenosylhomocysteine hydrolase deficiency in purine nucleoside phosphorylase and hypoxanthine-guanine phosphoribosyltransferase deficient patients. J Clin Invest 67: 696–701, 1981.
Zegers BJM, Stoop JW, Staal GEJ, Wadman SK: An approach to the restoration of T-cell function in a purine nucleoside phosphorylase deficient patient, in Enzyme Defects and Immune Dysfunction, Ciba Foundation Symposium No. 68. Amsterdam, Elsevier, 1979, pp 231–247.
Rich KC, Mejias E, Fox IH: Nucleoside phosphorylase deficiency: Improved immune function with enzyme replacement therapy. N Engl J Med 303: 973–977, 1980.
Kazmers IS, Mitchell BS, Dadonna PE, Wotring LL, Townsend LB, Kelly WN: Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine selective toxicity for T -lymphoblasts. Science 214: 1137–1139,1981.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Martinus Nijhoff Publishers, The Hague
About this chapter
Cite this chapter
Fox, I.H. (1983). Clinical Expression of Blocks of Purine Nucleotide Degradation. In: Berne, R.M., Rall, T.W., Rubio, R. (eds) Regulatory Function of Adenosine. Developments in Pharmacology, vol 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3909-0_15
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3909-0_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3911-3
Online ISBN: 978-1-4613-3909-0
eBook Packages: Springer Book Archive